Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05260437 · ClinicalTrials.gov registry record · Phase 1

Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants

A Phase 1 study of COVID-19 and SARS-CoV-2, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 1
Development phase
99
Enrollment target
20
Study locations

NCT05260437 is a Phase 1 study of COVID-19 and SARS-CoV-2 that has completed, run by GlaxoSmithKline. The registered enrollment target is 99 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05260437, a Phase 1 study of COVID-19 and SARS-CoV-2, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 1
Development phase
99 participants
Enrollment target
20
Study locations

Study Summary

Prevention of COVID-19 caused by SARS-CoV-2.

Conditions Studied

COVID-19 SARS-CoV-2

Interventions

  • BIOLOGICAL CV2CoV (2 µg)
  • BIOLOGICAL CV2CoV (4 µg)
  • BIOLOGICAL CV2CoV (8 µg)
  • BIOLOGICAL CV2CoV (12 µg)
  • BIOLOGICAL CV2CoV (16 µg)

Study Locations (20)

Florida

  • GSK Investigational Site - Hallandale
  • MD Clinical - Velocity - Hallandale
  • GSK Investigational Site - Lakeland
  • Accel Research Sites - Lakeland
  • GSK Investigational Site - Miami
  • Suncoast Research Group LLC - ERN-PPDS - Miami
  • GSK Investigational Site - Palm Springs

Oklahoma

  • GSK Investigational Site - Norman
  • Lynn Institute of Norman - ERN - PPDS - Norman
  • GSK Investigational Site - Oklahoma City
  • Lynn Health Science Institute - Oklahoma City

Texas

  • GSK Investigational Site - Cedar Park
  • GSK Investigational Site - Dallas
  • GSK Investigational Site - Dallas
  • Research Your Health - Elite - Plano

Illinois

  • Affinity Health Corp - Oak Brook
  • GSK Investigational Site - Oak Brook

Ohio

  • GSK Investigational Site - Cleveland
  • Velocity Clinical Research - Cleveland - Cleveland

Colorado

  • Lynn Institute of Denver - ERN - Aurora

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2022-03-24
Est. Completion 2023-03-07
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05260437

The ClinicalTrials.gov registry entry for NCT05260437 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 5 interventions - of which CV2CoV (2 µg) is the first listed.

NCT05260437 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, Oklahoma, Texas.

Frequently Asked Questions

What is clinical trial NCT05260437 about?

NCT05260437 is a clinical study titled "Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants". Prevention of COVID-19 caused by SARS-CoV-2.

What is the current status of trial NCT05260437?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2022-03-24. Estimated completion is 2023-03-07.

What conditions does trial NCT05260437 study?

This clinical trial studies the following conditions: COVID-19, SARS-CoV-2.

What interventions are being tested in trial NCT05260437?

The interventions under investigation include: CV2CoV (2 µg) (BIOLOGICAL), CV2CoV (4 µg) (BIOLOGICAL), CV2CoV (8 µg) (BIOLOGICAL), CV2CoV (12 µg) (BIOLOGICAL), CV2CoV (16 µg) (BIOLOGICAL).

Who is sponsoring clinical trial NCT05260437?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05260437 being conducted?

This trial has 20 study locations across Colorado, Florida, Illinois, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

COVID-19

All registered trials for this condition

SARS-CoV-2

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.